Preferential prescribing and utilization trends of diabetes medications among patients with renal impairment: Emerging role of linagliptin and other dipeptidyl peptidase 4 inhibitors.
Elisabetta PatornoChandrasekar GopalakrishnanDorothee B BartelsKimberly G BrodoviczJun LiuSebastian SchneeweissPublished in: Endocrinology, diabetes & metabolism (2017)
Among patients initiating newer diabetes medications between 05/2011-09/2015, those initiating linagliptin had the highest prevalence of moderate to severe renal impairment, suggesting preferential prescribing in routine care. DPP-4 inhibitors overall were among the most frequently chosen agents among T2DM patients with moderate to severe renal impairment between 01/2006-09/2015. Further investigation of the safety and effectiveness of DPP-4 inhibitors in routine care of T2DM patients with renal impairment is needed to either corroborate or discourage current prescribing patterns.
Keyphrases
- primary care
- type diabetes
- healthcare
- glycemic control
- cardiovascular disease
- palliative care
- randomized controlled trial
- clinical practice
- high intensity
- early onset
- risk factors
- adverse drug
- adipose tissue
- emergency department
- metabolic syndrome
- insulin resistance
- skeletal muscle
- weight loss
- electronic health record
- health insurance